Edition:
United States

Clearside Biomedical Inc (CLSD.OQ)

CLSD.OQ on NASDAQ Stock Exchange Global Market

6.32USD
22 Feb 2018
Change (% chg)

-- (--)
Prev Close
$6.32
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
53,781
52-wk High
$10.31
52-wk Low
$5.32

Chart for

About

Clearside Biomedical, Inc. is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company's product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid,... (more)

Overall

Beta: --
Market Cap(Mil.): $160.16
Shares Outstanding(Mil.): 25.34
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 192.73 16.31
EPS (TTM): -- -- --
ROI: -- -0.67 35.74
ROE: -- -3.38 17.71

BRIEF-Clearside Biomedical Q3 loss per share $0.72

* Clearside Biomedical, Inc. Announces third quarter 2017 financial results and provides corporate update

Nov 08 2017

BRIEF-Clearside Biomedical announces completion of patient enrollment in phase 2 clinical trial of CLS-TA

* Clearside Biomedical announces completion of patient enrollment in phase 2 clinical trial of CLS-TA used together with Eylea in patients with diabetic macular edema

Oct 24 2017

Earnings vs. Estimates